Core Viewpoint - The report from Guosen Securities indicates that the medical services and consumer-related sectors have experienced long-term adjustments, resulting in valuations at historical lows. By 2026, improvements in supply structure, increased treatment volumes, and store optimization are expected to lead to a dual recovery in fundamentals and valuations, with AI empowerment providing new momentum for leading companies [1][2]. Group 1: Medical Services and Consumer Sectors - The medical services and consumer-related sectors are currently undervalued and poised for performance recovery, with a focus on specific sub-sectors [2]. - In medical services, improvements in supply structure and consumer environment are anticipated to gradually revive business, with stable customer spending and increased treatment volumes. Leading companies are expected to provide positive earnings guidance for 2026, indicating a potential dual recovery in fundamentals and valuations. AI-related business developments are also expected to drive new growth for leading medical service firms. Key companies to watch include Aier Eye Hospital (300015), Gushengtang, Tongce Medical (600763), and Haijia Medical [2]. - The pharmacy sector has shown significant marginal improvement in performance since Q3 2025, with leading companies improving same-store performance quarterly. Regulatory support from nine ministries emphasizes the long-term development direction of industry concentration and chain rate enhancement, with non-pharmaceutical adjustments and store structure optimization driving short-term performance improvements. Key companies include Yifeng Pharmacy (603939) and Dazhenglin (603233) [2]. Group 2: Home Medical Devices - The growth of home medical device companies is driven by increased product penetration and domestic production rates. Rapid growth is observed in products like Continuous Glucose Monitors (CGM) and sleep apnea machines, with leading domestic brands expanding internationally. Traditional categories like blood pressure monitors are increasingly focusing on the high-end market, with domestic brands steadily increasing market share. The combination of high domestic growth and new overseas markets is expected to contribute to sustained performance growth for home medical device companies. Key companies include Yuyue Medical (002223), Kefu Medical (301087), Sanofi Biological (300298), and Ruimaite (301367) [3]. Group 3: Innovative Drug Development - The collaboration for the international expansion of innovative drugs continues to deepen, with recent significant agreements between Shiyao Group and AstraZeneca, as well as Innovent Biologics and Eli Lilly. These collaborations highlight the growing recognition of China's innovative drug development capabilities by multinational pharmaceutical companies, showcasing the efficiency and cost advantages of Chinese innovative drugs [4]. Group 4: Investment Portfolio for 2026 - The investment portfolio for 2026 includes A-shares such as Mindray Medical (300760), United Imaging Healthcare, WuXi AppTec (603259), New Industry (300832), Meihua Medical (301363), Adebiotech (300685), Zhend Medical (603301), Yaokang Biological, Kingmed Diagnostics (603882), Aier Eye Hospital, Yuyue Medical, Yifeng Pharmacy, and Dazhenglin; H-shares include Kangfang Biologics, Kelun-Botai Biologics-B, Hutchison China MediTech, Kangnuo-B, Sanofi Biopharma, Gushengtang, and Aikang Medical [5].

Core Viewpoint - The Shanghai 180 ETF Index Fund has shown significant growth in both scale and performance, with notable increases in net value and share volume, indicating strong investor interest and market confidence [1][3]. Performance Summary - As of February 11, 2026, the Shanghai 180 Index rose by 0.19%, with constituent stocks like China Jushi and Huayou Cobalt experiencing gains of 9.99% and 5.45% respectively [1]. - The Shanghai 180 ETF Index Fund has achieved a 14.74% increase in net value over the past six months, with a maximum monthly return of 9.13% since inception [1]. - The fund has a historical one-year profit probability of 100%, with an average monthly return of 3.08% and a monthly profit percentage of 75% [1]. Liquidity and Scale - The Shanghai 180 ETF Index Fund recorded a turnover rate of 0.43% with a trading volume of 24.91 million yuan on February 11, 2026, and an average daily trading volume of 70.58 million yuan over the past week [1]. - The fund's scale has increased by 32.33 million yuan over the past year, ranking second among comparable funds [1]. Share Growth - The number of shares for the Shanghai 180 ETF Index Fund has grown by 21 million shares in the past year, also ranking second among comparable funds [1]. Risk and Fee Structure - The fund's management fee is 0.15% and the custody fee is 0.05%, which are among the lowest in comparable funds [3]. - The maximum drawdown for the fund this year is 4.28%, with a tracking error of 0.019% over the past three months, indicating high tracking precision [3]. Top Holdings - As of January 30, 2026, the top ten weighted stocks in the Shanghai 180 Index account for 24.85% of the index, with major companies including Zijin Mining and Kweichow Moutai [3].

Group 1 - The stock price of Reborn Biotech (06938.HK) increased by 13.65% [1] - WuXi Biologics (02269.HK) saw a rise of 4.83% in its stock price [1] - Baosai Tu-B (02315.HK) experienced a stock price increase of 3.88% [1] - WuXi AppTec (02359.HK) had a stock price growth of 3.15% [1]

Core Insights - The report emphasizes the focus on undervalued and performance-recovering sectors within the medical services and consumer segments, predicting a fundamental improvement in 2026 [4]. Group 1: Investment Strategy - The report maintains an "outperform" rating for the sector, indicating a positive outlook for the medical and consumer-related segments [2]. - Key areas of focus include medical services, pharmacies, and home medical devices, which are expected to see performance recovery and valuation improvements in 2026 [4]. Group 2: Sector Analysis - Medical services are anticipated to recover due to improved supply structure and consumer environment, with leading companies expected to show positive earnings guidance for 2026 [4]. - The pharmacy sector has shown significant marginal improvement since Q3 2025, with leading companies experiencing quarterly performance enhancements [4]. - Home medical devices are expected to benefit from increased product penetration and domestic production rates, contributing to sustained performance growth [4]. Group 3: Notable Companies - The report highlights specific companies to watch, including Aier Eye Hospital, Yuyue Medical, and Yifeng Pharmacy, which are positioned for growth in their respective segments [4]. - The investment portfolio for February 2026 includes a mix of A-share and H-share companies, such as Mindray Medical, WuXi AppTec, and Kangfang Biotech, indicating a diversified approach to investment [4]. Group 4: Market Performance - The medical sector outperformed the broader market in January 2026, with a 3.14% increase compared to the 1.49% rise of the CSI 300 index [10]. - Sub-sectors such as medical services and medical devices showed significant gains, with respective increases of 8.82% and 5.28% [17]. Group 5: Macro Data - In 2025, the pharmaceutical manufacturing industry reported a total revenue of 24,870 billion yuan, reflecting a slight decline of 1.2% year-on-year, while total profits increased by 2.7% [9]. - The retail sales of pharmaceuticals reached 7,294 billion yuan, with a year-on-year growth of 1.8%, indicating a stable demand in the market [9].

传媒板块大涨，数字王国大涨29%，阅文集团涨逾15%，大麦娱乐涨超6%。 | 名称 | 涨跌幅 ▼ | 现价 | | --- | --- | --- | | 数字于国 | 29.31% | 0.375c | | 毛记葵涌 | 21.92% | 0.890c | | 万咖膏联 | 20.00% | 1.560c | | 中国国家文化产业 | 18.18% | 0.780c | | 阅文集团 | 15.41% | 43.580c | | 环球数码创意 | 9.09% | 0.072c | | 普乐师集团控股 | 8.76% | 5.710c | | 橙天嘉禾 | 7.81% | 0.069c | | 大麦娱乐 | 6.12% | 1.040c | | 新传企划 | 5.71% | 0.370c | | 中国儒意 | 5.63% | 2.250c | | 柠萌影视 | 5.42% | 3.500c | | 乐思集团 | 4.81% | 1.090c | | 丰德丽控股 | 4.17% | 0.050c | | 稻草熊娱乐 | 3.75% | 0.415c | | 大象未来集团 | 3.72% | 2.230c | ...

2月11日，港股医药有所分化。创新药大面积回调，创新药纯度100%的港股通创新药ETF（520880）微 跌0.19%止步三连阳。医疗主题板块继续上行，港股通医疗ETF华宝（159137）走出四连涨，站上20日 均线。 | 分时 多日 1分 5分 15分 30分 · 给会屏 F9 后复农 超级盘加 面试 工具 @ (1) > | | 港般通医疗ETF华宝 | | 159137 | | --- | --- | --- | --- | --- | | 159137.SZ[桃投通四疗ETF华宜] 2026/02/11 歌 1.024 幅0.49%(0.005) 开 1.025 高 1.030 低 1.019 均回 | | | | | | MAS 1.0021 MA10 0.998 MA20 1.022 2026/01/12-2026/02/11(23日)▼ | | 0 | | +0.005 +0.499 | | | 1,160 | SZSE CNY 15:00:00 闭槽 | | T+0 / 0 | | 4-1,152 | | 净值走势 | | 华宝中证港股通医疗主题ETF | | | | DEF | -51.86 ...

Market Overview - The Hong Kong stock market showed positive movement with the Hang Seng Index rising by 0.31% to close at 27,266.38 points, while the Hang Seng Tech Index increased by 0.90% to 5,499.99 points, and the Hang Seng China Enterprises Index rose by 0.28% to 9,268.18 points [2] - The total market turnover was HKD 217.22 billion, a decrease from the previous trading day's turnover of HKD 234.04 billion [2] Stock Performance - Among the constituents of the Hang Seng Index, 62 stocks rose while 23 fell. Notable gainers included: - Techtronic Industries, up 4.90% with a turnover of HKD 2.105 billion and a year-to-date increase of 33.37% [3][4] - Xiaomi Group, up 4.27% with a turnover of HKD 8.259 billion and a year-to-date decrease of 5.60% [4] - Link REIT, up 3.83% with a turnover of HKD 1.136 billion and a year-to-date increase of 6.16% [4] - On the downside, Pop Mart fell by 5.49%, China Life by 3.94%, and Shenzhou International by 2.22% [3] Regulatory Alert - The Hong Kong Securities and Futures Commission (SFC) issued a warning about fraudulent stock analysts impersonating reputable figures to promote high-return investment schemes, leading to potential scams [5][6] - The SFC has reported cases where fraudsters use social media to lure victims into "pump and dump" schemes, where they artificially inflate stock prices before selling off their shares [6][7] - The SFC has filed a report with the police and is collaborating with law enforcement to combat investment fraud [7] Company Financials - NetEase reported a total revenue of RMB 112.6 billion for the year, with Q4 revenue of RMB 27.5 billion. The company achieved an operating profit of RMB 35.8 billion for the year, a 21% increase year-on-year [10] - The gaming and related services revenue reached RMB 92.1 billion, with online gaming net revenue of RMB 89.6 billion, marking an 11% year-on-year growth [10] - Semiconductor manufacturer SMIC reported a net profit increase of 60.7% year-on-year, despite a stock price decline of over 2% following the earnings announcement [10][13]

Market Overview - The Hang Seng Index closed at 27,183, up 0.58%, maintaining above the 27,000 mark[9] - The S&P 500 index fell by 0.33%, while the Nasdaq dropped by 0.59%[9] - The Dow Jones index increased slightly, reaching a new historical high[9] Retail Sector Performance - U.S. retail sales in December remained flat month-on-month, missing the expected growth of 0.4% and down from a previous increase of 0.6% in November[9] - Costco and Walmart saw declines of over 2% and 1%, respectively, due to the disappointing retail data[9] Technology Sector Insights - Hong Kong tech stocks continued to recover, with Alibaba and JD.com both rising approximately 2%[9] - AI application stocks performed strongly, with the stock of Yueda Group surging over 15%[9] Biopharmaceutical Sector Trends - The biopharmaceutical sector saw widespread gains, with companies like WuXi Biologics and Innovent Biologics also experiencing significant increases[9] - Upcoming earnings disclosures in February and March are expected to show improved performance for several innovative drug companies[9] Economic Indicators - The employment cost index in Q4 reached its lowest growth in four years, indicating potential economic weakness[12] - The Cleveland Fed President suggested that the Federal Reserve may keep interest rates unchanged for an extended period[12]

Group 1 - The article highlights the top three companies with the highest AH premium rates: Northeast Electric (00042) at 831.03%, Beijing Jingcheng Machinery Electric (00187) at 291.45%, and Sinopec Oilfield Service (01033) at 288.17% [1] - The bottom three companies with the lowest AH premium rates are Contemporary Amperex Technology (03750) at -12.59%, WuXi AppTec (02359) at -4.58%, and China Merchants Bank (03968) at -4.48% [1] - The article provides a detailed ranking of the top ten and bottom ten AH stocks based on their premium rates and deviation values, indicating significant disparities in market valuations between H-shares and A-shares [1][2] Group 2 - The deviation values for the top three companies are Beijing Jingcheng Machinery Electric (00187) at 27.77%, Jinju Group (02009) at 19.35%, and Kai Sheng New Energy (01108) at 16.80% [1] - The bottom three companies with the most negative deviation values are Junda Co., Ltd. (02865) at -60.53%, Chenming Paper (01812) at -32.02%, and CNOOC Services (02883) at -31.42% [1][2] - The article emphasizes that the deviation value represents the difference between the current premium rate and the average premium rate over the past 30 days, providing insights into market trends [2]

AI 制药前景探索 20260210 摘要 AI 制药公司通过提供算法能力与大型药企合作，早期以研发外包为主， 现转向管线服务或 IP 收购，传统软件服务如计算方法工具仍不可或缺。 国内公司如金泰提供 APP 活性评估软件和管线里程碑服务，现金流主要 来自 FTE 人工合成。 AI 制药能加速 PCC 研发，如 FEP 可快速评估活性，减少实验量。国外 AI 制药技术成熟，国内算法成熟但小分子应用少，市场主要在国外，国 内企业逐步接受。 国外以薛定谔为代表销售高价软件，国内市场探索中，未来或采用类似 模式但推广较慢。国内企业不广泛使用类似软件的原因是大分子管线为 主，对计算方法理解有限。 AI 制药中数据和算法密不可分，有价值的数据需案例积累并纳入内部数 据集，算法本身也是一种数据。弯道超车赶超薛定谔等公司非常困难， 需长期积累案例和方法论。 薛定谔公司产品不断更新，提高计算精准度和可信度，减少实验失败风 险。CADD 领域大模型带来新机会，可自动解析专利，节省人工阅读时 间。 Q&A 如何评价国内 AI 制药研发平台，如英西和金泰等公司的能力？ 在 AI 制药领域，英西实际上是一家药企，而非真正的算法平台公 ...